Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma

Immune Checkpoint Inhibitor (ICI) therapy has revolutionized treatment for advanced melanoma; however, only a subset of patients benefit from this treatment. Despite considerable efforts, the Tumor Mutation Burden (TMB) is the only FDA-approved biomarker in melanoma. However, the mechanisms underlyi...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Andrew, Auslander, Noam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485158/
https://www.ncbi.nlm.nih.gov/pubmed/36123351
http://dx.doi.org/10.1038/s41467-022-32838-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485158/
https://www.ncbi.nlm.nih.gov/pubmed/36123351
http://dx.doi.org/10.1038/s41467-022-32838-4

Ejemplares similares